Abstract COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused
over 5 million deaths to date. Although multiple vaccines are available, breakthrough …

Monoclonal antibodies are a promising approach to treat COVID-19, however the
emergence of SARS-CoV-2 variants has challenged the efficacy and future of these …

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

Monoclonal antibodies are an efficacious therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape …

The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants
has sparked concern over the continued effectiveness of existing therapeutic antibodies and …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages
that are more transmissible and resistant to currently approved antibody therapies poses a …

SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …

Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide
range of biomedical applications involving novel coronavirus disease (COVID-19) …

Understanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for
effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb …